Cowen & Co. analyst Joseph Thome initiates coverage on Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform rating.
Deutsche Bank Maintains Buy on Microsoft, Lowers Price Target to $275
Deutsche Bank analyst Brad Zelnick maintains Microsoft (NASDAQ:MSFT) with a Buy and lowers the price target from $315 to $275.